PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32553670-0	2021	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice.	Seladelpar	33-43	peroxisome proliferator activator receptor delta	Mus musculus	14-24	
32553670-3	2021	Here, we evaluated the effect of the selective PPAR-delta agonist seladelpar (MBX-8025) on gut barrier function and bile acid metabolism in a mouse model of ethanol-induced liver disease.	Seladelpar	66-76	peroxisome proliferator activator receptor delta	Mus musculus	47-57	
32553670-11	2021	Data from this study demonstrates that seladelpar prevents and treats ethanol-induced liver damage in mice by direct PPARdelta agonism in both the liver and the intestine.	Seladelpar	39-49	peroxisome proliferator activator receptor delta	Mus musculus	117-126	
35605662-0	2022	Selective PPARdelta agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway.	Seladelpar	28-38	peroxisome proliferator activator receptor delta	Mus musculus	10-19	
35605662-7	2022	The suppressive effect of seladelpar on Cyp7a1 expression was blocked by a JNK inhibitor as well as in the absence of Fgf21, indicating that Fgf21 plays an indispensable role in PPARdelta-mediated downregulation of Cyp7a1.	Seladelpar	26-36	peroxisome proliferator activator receptor delta	Mus musculus	178-187	
29404484-0	2017	The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.	Seladelpar	71-81	peroxisome proliferator activator receptor delta	Mus musculus	14-62	
29404484-3	2017	Seladelpar (MBX-8025), a selective PPAR-delta agonist, improves atherogenic dyslipidemia.	Seladelpar	0-10	peroxisome proliferator activator receptor delta	Mus musculus	35-45